Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics

Ultragenyx Pharmaceutical Inc. (RARE): $50.06

0.45 (+0.91%)

POWR Rating

Component Grades








Add RARE to Watchlist
Sign Up

Industry: Biotech




#104 of 380

in industry

RARE Price/Volume Stats

Current price $50.06 52-week high $68.68
Prev. close $49.61 52-week low $33.36
Day low $49.90 Volume 53,715
Day high $51.47 Avg. volume 627,771
50-day MA $43.86 Dividend yield N/A
200-day MA $42.74 Market Cap 3.54B

RARE Stock Price Chart Interactive Chart >


  • RARE scores best on the Momentum dimension, with a Momentum rank ahead of 78.35% of US stocks.
  • The strongest trend for RARE is in Growth, which has been heading up over the past 179 days.
  • RARE's current lowest rank is in the Sentiment metric (where it is better than 31.48% of US stocks).

RARE Stock Summary

  • The ratio of debt to operating expenses for ULTRAGENYX PHARMACEUTICAL INC is higher than it is for about merely 7.69% of US stocks.
  • With a price/sales ratio of 9.22, ULTRAGENYX PHARMACEUTICAL INC has a higher such ratio than 88.45% of stocks in our set.
  • With a year-over-year growth in debt of -27.35%, ULTRAGENYX PHARMACEUTICAL INC's debt growth rate surpasses just 12.05% of about US stocks.
  • Stocks that are quantitatively similar to RARE, based on their financial statements, market capitalization, and price volatility, are STRO, ALGS, FDMT, VACC, and ONCT.
  • RARE's SEC filings can be seen here. And to visit ULTRAGENYX PHARMACEUTICAL INC's official web site, go to www.ultragenyx.com.

RARE Valuation Summary

  • In comparison to the median Healthcare stock, RARE's price/sales ratio is 331.82% higher, now standing at 9.5.
  • RARE's price/earnings ratio has moved up 18.5 over the prior 113 months.

Below are key valuation metrics over time for RARE.

Stock Date P/S P/B P/E EV/EBIT
RARE 2023-05-23 9.5 16.5 -5.1 -5.0
RARE 2023-05-22 9.4 16.3 -5.0 -5.0
RARE 2023-05-19 9.2 16.0 -4.9 -4.9
RARE 2023-05-18 9.4 16.4 -5.0 -5.0
RARE 2023-05-17 9.1 15.8 -4.8 -4.8
RARE 2023-05-16 8.6 15.0 -4.6 -4.6

RARE Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -44.85%.
  • The year over year price growth rate now stands at -45.72%.
  • Its 5 year revenue growth rate is now at 91517.29%.
RARE's revenue has moved up $239,656,000 over the prior 33 months.

The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 343.37 -344.467 -678.046
2022-06-30 334.314 -308.771 -505.938
2022-03-31 331.946 -296.87 -470.204
2021-12-31 351.406 -338.695 -454.025
2021-09-30 359.559 -346.803 -355.578
2021-06-30 359.382 -349.121 -351.425

RARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
  • RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
  • ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.

The table below shows RARE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.234 0.955 -0.414
2021-03-31 0.225 0.956 -0.267
2020-12-31 0.194 0.977 -0.277
2020-09-30 0.174 0.973 -0.420
2020-06-30 0.140 0.962 -0.540
2020-03-30 0.116 0.959 -0.769

RARE Price Target

For more insight on analysts targets of RARE, see our RARE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.67 Average Broker Recommendation 1.58 (Moderate Buy)

Ultragenyx Pharmaceutical Inc. (RARE) Company Bio

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.

RARE Latest News Stream

Event/Time News Detail
Loading, please wait...

RARE Latest Social Stream

Loading social stream, please wait...

View Full RARE Social Stream

Latest RARE News From Around the Web

Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit

NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer, will present at the 2023 Barclays - Gene Editing & Gene Therapy Summit on Wednesday, May 24, 2023, at 8:50 a.m. ET. The live and archived webcast of the panel will be accessible fro

Yahoo | May 19, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 810 shares of common stock of the company and 31,690 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by

Yahoo | May 18, 2023

Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing

Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.

Yahoo | May 18, 2023

Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.

Amended U.S. protocol increases loading and maintenance doses to similar range as ex-U.S. expansion cohortsNOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol amendment to the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome that enables the company to harmonize dose ranges in the U.S. with those being used in ex-U.S. cohorts of

Yahoo | May 17, 2023

Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Yahoo | May 15, 2023

Read More 'RARE' Stories Here

RARE Price Returns

1-mo 15.53%
3-mo 9.54%
6-mo 24.62%
1-year 0.20%
3-year -33.33%
5-year -32.10%
YTD 8.05%
2022 -44.90%
2021 -39.25%
2020 224.12%
2019 -1.77%
2018 -6.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!